Analyzing Nyxoah (NASDAQ:NYXH) & Schrodinger (NASDAQ:SDGR)

Nyxoah (NASDAQ:NYXH) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nyxoah and Schrodinger, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	1	2	0	2.25
Schrodinger	1	4	4	0	2.33

Nyxoah presently has a consensus price target of $7.67, suggesting a potential upside of 472.14%. Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 39.46%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than Schrodinger.

Insider & Institutional Ownership

79.1% of Schrodinger shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Nyxoah and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Schrodinger	-40.61%	-30.85%	-15.32%

Volatility and Risk

Nyxoah has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Earnings and Valuation

This table compares Nyxoah and Schrodinger”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33 million	3.39	-$101.92 million	($2.48)	-0.54
Schrodinger	$255.87 million	4.19	-$103.26 million	($1.41)	-10.30

Nyxoah has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Summary

Schrodinger beats Nyxoah on 10 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.